Bloom Burton analyst David Martin reinstated Repare Therapeutics with a Buy rating, up from a previous Accumulate, noting that shares are trading at half of pro-forma cash and highlighting a “broad pipeline with multiple 2024 data points.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX:
Questions or Comments about the article? Write to editor@tipranks.com